Cargando…

BMI and Treatment Response in Patients With Pulmonary Arterial Hypertension: A Meta-analysis

BACKGROUND: Obesity is increasingly prevalent in pulmonary arterial hypertension (PAH) but is associated with improved survival, creating an “obesity paradox” in PAH. It is unknown if the improved outcomes could be attributable to obese patients deriving a greater benefit from PAH therapies. RESEARC...

Descripción completa

Detalles Bibliográficos
Autores principales: McCarthy, Breanne E., McClelland, Robyn L., Appleby, Dina H., Moutchia, Jude S., Minhas, Jasleen K., Min, Jeff, Mazurek, Jeremy A., Smith, K. Akaya, Fritz, Jason S., Pugliese, Steven C., Urbanowicz, Ryan J., Holmes, John H., Palevsky, Harold I., Kawut, Steven M., Al-Naamani, Nadine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American College of Chest Physicians 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9470735/
https://www.ncbi.nlm.nih.gov/pubmed/35247393
http://dx.doi.org/10.1016/j.chest.2022.02.041
_version_ 1784788909837778944
author McCarthy, Breanne E.
McClelland, Robyn L.
Appleby, Dina H.
Moutchia, Jude S.
Minhas, Jasleen K.
Min, Jeff
Mazurek, Jeremy A.
Smith, K. Akaya
Fritz, Jason S.
Pugliese, Steven C.
Urbanowicz, Ryan J.
Holmes, John H.
Palevsky, Harold I.
Kawut, Steven M.
Al-Naamani, Nadine
author_facet McCarthy, Breanne E.
McClelland, Robyn L.
Appleby, Dina H.
Moutchia, Jude S.
Minhas, Jasleen K.
Min, Jeff
Mazurek, Jeremy A.
Smith, K. Akaya
Fritz, Jason S.
Pugliese, Steven C.
Urbanowicz, Ryan J.
Holmes, John H.
Palevsky, Harold I.
Kawut, Steven M.
Al-Naamani, Nadine
author_sort McCarthy, Breanne E.
collection PubMed
description BACKGROUND: Obesity is increasingly prevalent in pulmonary arterial hypertension (PAH) but is associated with improved survival, creating an “obesity paradox” in PAH. It is unknown if the improved outcomes could be attributable to obese patients deriving a greater benefit from PAH therapies. RESEARCH QUESTION: Does BMI modify treatment effectiveness in PAH? STUDY DESIGN AND METHODS: Using individual participant data, a meta-analysis was conducted of phase III, randomized, placebo-controlled trials of treatments for PAH submitted for approval to the U.S. Food and Drug Administration from 2000 to 2015. Primary outcomes were change in 6-min walk distance (6MWD) and World Health Organization (WHO) functional class. RESULTS: A total of 5,440 participants from 17 trials were included. Patients with overweight and obesity had lower baseline 6MWD and were more likely to be WHO functional class III or IV. Treatment was associated with a 27.01-m increase in 6MWD (95% CI, 21.58-32.45; P < .001) and lower odds of worse WHO functional class (OR, 0.58; 95% CI, 0.48-0.70; P < .001). For every 1 kg/m(2) increase in BMI, 6MWD was reduced by 0.66 m (P = .07); there was no significant effect modification of treatment response in 6MWD according to BMI (P for interaction = .34). Higher BMI was not associated with odds of WHO functional class at end of follow-up; however, higher BMI attenuated the treatment response such that every 1 kg/m(2) increase in BMI increased odds of worse WHO functional class by 3% (OR, 1.03; P for interaction = .06). INTERPRETATION: Patients with overweight and obesity had lower baseline 6MWD and worse WHO functional class than patients with normal weight with PAH. Higher BMI did not modify the treatment response for change in 6MWD, but it attenuated the treatment response for WHO functional class. PAH trials should include participants representative of all weight groups to allow for assessment of treatment heterogeneity and mechanisms.
format Online
Article
Text
id pubmed-9470735
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American College of Chest Physicians
record_format MEDLINE/PubMed
spelling pubmed-94707352022-09-19 BMI and Treatment Response in Patients With Pulmonary Arterial Hypertension: A Meta-analysis McCarthy, Breanne E. McClelland, Robyn L. Appleby, Dina H. Moutchia, Jude S. Minhas, Jasleen K. Min, Jeff Mazurek, Jeremy A. Smith, K. Akaya Fritz, Jason S. Pugliese, Steven C. Urbanowicz, Ryan J. Holmes, John H. Palevsky, Harold I. Kawut, Steven M. Al-Naamani, Nadine Chest Pulmonary Vascular: Original Research BACKGROUND: Obesity is increasingly prevalent in pulmonary arterial hypertension (PAH) but is associated with improved survival, creating an “obesity paradox” in PAH. It is unknown if the improved outcomes could be attributable to obese patients deriving a greater benefit from PAH therapies. RESEARCH QUESTION: Does BMI modify treatment effectiveness in PAH? STUDY DESIGN AND METHODS: Using individual participant data, a meta-analysis was conducted of phase III, randomized, placebo-controlled trials of treatments for PAH submitted for approval to the U.S. Food and Drug Administration from 2000 to 2015. Primary outcomes were change in 6-min walk distance (6MWD) and World Health Organization (WHO) functional class. RESULTS: A total of 5,440 participants from 17 trials were included. Patients with overweight and obesity had lower baseline 6MWD and were more likely to be WHO functional class III or IV. Treatment was associated with a 27.01-m increase in 6MWD (95% CI, 21.58-32.45; P < .001) and lower odds of worse WHO functional class (OR, 0.58; 95% CI, 0.48-0.70; P < .001). For every 1 kg/m(2) increase in BMI, 6MWD was reduced by 0.66 m (P = .07); there was no significant effect modification of treatment response in 6MWD according to BMI (P for interaction = .34). Higher BMI was not associated with odds of WHO functional class at end of follow-up; however, higher BMI attenuated the treatment response such that every 1 kg/m(2) increase in BMI increased odds of worse WHO functional class by 3% (OR, 1.03; P for interaction = .06). INTERPRETATION: Patients with overweight and obesity had lower baseline 6MWD and worse WHO functional class than patients with normal weight with PAH. Higher BMI did not modify the treatment response for change in 6MWD, but it attenuated the treatment response for WHO functional class. PAH trials should include participants representative of all weight groups to allow for assessment of treatment heterogeneity and mechanisms. American College of Chest Physicians 2022-08 2022-03-03 /pmc/articles/PMC9470735/ /pubmed/35247393 http://dx.doi.org/10.1016/j.chest.2022.02.041 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Pulmonary Vascular: Original Research
McCarthy, Breanne E.
McClelland, Robyn L.
Appleby, Dina H.
Moutchia, Jude S.
Minhas, Jasleen K.
Min, Jeff
Mazurek, Jeremy A.
Smith, K. Akaya
Fritz, Jason S.
Pugliese, Steven C.
Urbanowicz, Ryan J.
Holmes, John H.
Palevsky, Harold I.
Kawut, Steven M.
Al-Naamani, Nadine
BMI and Treatment Response in Patients With Pulmonary Arterial Hypertension: A Meta-analysis
title BMI and Treatment Response in Patients With Pulmonary Arterial Hypertension: A Meta-analysis
title_full BMI and Treatment Response in Patients With Pulmonary Arterial Hypertension: A Meta-analysis
title_fullStr BMI and Treatment Response in Patients With Pulmonary Arterial Hypertension: A Meta-analysis
title_full_unstemmed BMI and Treatment Response in Patients With Pulmonary Arterial Hypertension: A Meta-analysis
title_short BMI and Treatment Response in Patients With Pulmonary Arterial Hypertension: A Meta-analysis
title_sort bmi and treatment response in patients with pulmonary arterial hypertension: a meta-analysis
topic Pulmonary Vascular: Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9470735/
https://www.ncbi.nlm.nih.gov/pubmed/35247393
http://dx.doi.org/10.1016/j.chest.2022.02.041
work_keys_str_mv AT mccarthybreannee bmiandtreatmentresponseinpatientswithpulmonaryarterialhypertensionametaanalysis
AT mcclellandrobynl bmiandtreatmentresponseinpatientswithpulmonaryarterialhypertensionametaanalysis
AT applebydinah bmiandtreatmentresponseinpatientswithpulmonaryarterialhypertensionametaanalysis
AT moutchiajudes bmiandtreatmentresponseinpatientswithpulmonaryarterialhypertensionametaanalysis
AT minhasjasleenk bmiandtreatmentresponseinpatientswithpulmonaryarterialhypertensionametaanalysis
AT minjeff bmiandtreatmentresponseinpatientswithpulmonaryarterialhypertensionametaanalysis
AT mazurekjeremya bmiandtreatmentresponseinpatientswithpulmonaryarterialhypertensionametaanalysis
AT smithkakaya bmiandtreatmentresponseinpatientswithpulmonaryarterialhypertensionametaanalysis
AT fritzjasons bmiandtreatmentresponseinpatientswithpulmonaryarterialhypertensionametaanalysis
AT pugliesestevenc bmiandtreatmentresponseinpatientswithpulmonaryarterialhypertensionametaanalysis
AT urbanowiczryanj bmiandtreatmentresponseinpatientswithpulmonaryarterialhypertensionametaanalysis
AT holmesjohnh bmiandtreatmentresponseinpatientswithpulmonaryarterialhypertensionametaanalysis
AT palevskyharoldi bmiandtreatmentresponseinpatientswithpulmonaryarterialhypertensionametaanalysis
AT kawutstevenm bmiandtreatmentresponseinpatientswithpulmonaryarterialhypertensionametaanalysis
AT alnaamaninadine bmiandtreatmentresponseinpatientswithpulmonaryarterialhypertensionametaanalysis